![David Preston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Preston active positions
Companies | Position | Start | End |
---|---|---|---|
Cell Therapy Ltd.
![]() Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Director/Board Member | 2015-01-19 | - |
Corporate Secretary | 2015-01-19 | - | |
Celixir Plc
![]() Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Chief Operating Officer | - | - |
Corporate Secretary | - | - |
Career history of David Preston
Statistics
International
United Kingdom | 3 |
Operational
Corporate Secretary | 2 |
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Cell Therapy Ltd.
![]() Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
Celixir Plc
![]() Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- David Preston
- Experience